Call for Abstract
20th World Congress on Pharmaceutical Sciences and Innovations in Pharma Industry, will be organized around the theme “New Challenges in Pharma Industries and Growth of Pharmaceutical Research”
Pharmaceutical Sciences 2020 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Pharmaceutical Sciences 2020
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
The pharmaceutical industry is responsible for the development, production and marketing of medications. Thus, its immense importance as a global sector is evident. Pharmaceutical Industry includes venture that produce synthetic and plant derived preparations, vitamins, antibiotics, blood constituents, drugs in various dosage forms .They are subjected to a variety of laws and regulations that govern the patenting, testing, safety, competence and marketing of drugs. Pharmaceutical Sciences deals with accelerated research to discover new drugs. The industry and volume of productivity is determined by its capital etc. Evolution and elevation in pharmaceutical industry helps in controlling and treating the diseases.
Insights and actualities about the pharmaceutical business around the world
The pharmaceutical business is in charge of the improvement, creation and showcasing of prescriptions. In this way, its massive significance as a worldwide segment is apparent. The aggregate level of pharmaceutical income worldwide had achieved about one trillion U.S. dollars. North America is in charge of the biggest part, producing more than 40 percent of these incomes. This is for the most part because of the main part of the U.S. pharmaceutical industry. Be that as it may, as in numerous different ventures, the Chinese pharmaceutical segment demonstrates the most elevated development rates in the course of the most recent years.
- Track 1-1The Changing Healthcare Scene & Impact on the Pharmaceutical Industry
- Track 1-2The Europe Pharmaceutical Industry Is Rising to Its Challenges
- Track 1-3Universal Pharmaceutical Trade
- Track 1-4Pharmaceutical Analytical and QA Consulting services
- Track 1-5Key issues facing the Pharmaceutical Industry
- Track 1-6Pharma Tech Transfer
Drug discovery is a process, which aims at identifying a compound therapeutically useful in treating and curing a disease. Typically a drug discovery effort addresses a biological target that has been shown to play a role in the development of the disease or starts from a molecule with interesting biological activities.
The process of drug discovery involves the identification of candidates, synthesis, characterization, screening, and assays for therapeutic efficacy. Once a compound has shown its value in these tests, it will begin the process of drug development prior to clinical trials. Drug discovery and development is an expensive process due to the high costs of R&D and human clinical tests. The average total cost per drug development varies from US$ 897 million to US$ 1.9 billion. The typical development time is 10-15 years. In the past most drugs have been discovered either by identifying the active ingredient from traditional remedies or by serendipitous discovery. At present a new approach is being tried to understand how disease and infection are controlled at the molecular and physiological level and to target specific entities based on this knowledge.
The worldwide market for medication revelation advancements and items came to $38.4 billion in 2011. It has extended to $41.4 billion in 2012 and to $79.0 billion by 2017, a compound yearly development rate (CAGR) of 13.8% somewhere around 2012 and 2017.
- Track 2-1Steps in Modern Drug Discovery
- Track 2-2Lead Discovery Methods
- Track 2-3Advanced Technologies involved in Drug Discovery
Each year many new prescription drugs are approved by the Food and Drug Administration (FDA). The process of developing and bringing new drugs to market is important for primary care physicians to understand. A drug must undergo rigorous testing prior to marketing to and medical use by the general public. The process starts with preclinical testing. For drugs that appear safe, an investigational new drug application is filed with the FDA. If approved, clinical trials begin with phase 1 studies that focus on safety and pharmacology. Phase 2 studies examine the effectiveness of the compound. Phase 3 is the final step before submitting a new drug application (NDA) to the FDA. An NDA contains all the information obtained during all phases of testing. Phase 4 studies, or postmarketing studies, are conducted after a product is approved. Recent changes in legislation have streamlined the approval process. Critics contend that these changes have compromised public safety, resulting in the need to recall several products from the market. Proponents claim that changes in the approval process help patients with debilitating diseases, such as acquired immunodeficiency syndrome, that were previously denied critical medication because of bureaucratic regulations.
The worldwide market for medication disclosure in pharmaceuticals came to about $25.0 billion in 2013. This market is relied upon to reach $29.6 billion in 2014 and $79.8 billion in 2019, with a compound yearly development rate (CAGR) of 22.0% for the time of 2014 to 2019.
- Track 3-1Discovery and Development
- Track 3-2Preclinical Research
- Track 3-3Clinical Research
- Track 3-4FDA Review
- Track 3-5Drug Development Research
- Track 3-6Drug Characterisation
- Track 3-7Drug Designing and Targeting
The pharmaceutical sciences combine broad range of scientific disciplines that are critical to the discovery and development of new drugs and therapies. Pharmaceutical Sciences is a dynamic and interdisciplinary field that aims to integrate fundamental principles of physical and organic chemistry, engineering, biochemistry, and biology to understand how to optimize delivery of drugs to the body and translate this integrated understanding into new and improved therapies against human disease. At the many of institutes internationally recognized faculty contribute to the field through inquiry into the underlying mechanisms of drug interactions with the human body and development of advanced synthetic or biologically-derived materials that can modulate these interactions in pursuit of better and safer therapies and drug products.
The worldwide market for pharmaceutical science instruments and reagents came to $47.8 billion in 2012. This figure is relied upon to increment to $51.3 billion in 2013 and $77.6 billion in 2018, with an anticipated five-year compound yearly development rate (CAGR) of 8.6%.
- Track 4-1Preformulation and Formulation
- Track 4-2Routes of Drug Delivery
- Track 4-3Drug Designing and Targeting
- Track 4-4Bioavalibility and Bioequivalence
The most fundamental goal in drug design is to predict whether a given molecule will bind to a target and if so how strongly. Molecular mechanics or molecular dynamics are most often used to predict the conformation of the small molecule and to model conformational changes in the biological target that may occur when the small molecule binds to it. The therapeutic response of a drug depends upon the interaction of drug molecules with cell on cell membrane related biological events at receptor sites in concentration dependent manner.
Selective and effective localization of the pharmacologically-active moiety at preidentified target(s) in therapeutic concentration, while restricting its access to non-target(s) normal cellular linings, thus minimizing toxic effects and maximizing the therapeutic index accounts from effective and efficient drug delivery.
Molecular mechanics methods may also be used to provide semi-quantitative prediction of the binding affinity. Also, knowledge-based scoring function may be used to provide binding affinity estimates. These methods use linear regression, machine learning, neural nets or other statistical techniques to derive predictive binding affinity equations by fitting experimental affinities to computationally derived interaction energies between the small molecule and the target.
Ideally, the computational method will be able to predict affinity before a compound is synthesized and hence in theory only one compound needs to be synthesized, saving enormous time and cost. The reality is that present computational methods are imperfect and provide, at best, only qualitatively accurate estimates of affinity. In practice it still takes several iterations of design, synthesis, and testing before an optimal drug is discovered. Computational methods have accelerated discovery by reducing the number of iterations required and have often provided novel structures.
- Track 5-1Factors influencing Drug Targeting
- Track 5-2Advances in Drug Targeting components
- Track 5-3Recent Approaches to Drug Targeting
- Track 5-4Rational Drug Design
- Track 5-5Computer Aided Drug Design
- Track 5-6Drug Design Theory
- Track 5-7Role of Computers in Drug Design: Their Success and Failure
- Track 5-8Rational Drug Design Software
- Track 5-9RACHEL Software Package
Drug particles in the nanometer size range have unique characteristics that can lead to enhanced performance in a variety of dosage forms. Formulated correctly, particles in this size range are resistant to settling and can have higher saturation solubility, rapid dissolution, and enhanced adhesion to biological surfaces, thereby providing a rapid onset of therapeutic action and improved bioavailability. Scientists at Cirrus Pharmaceuticals, Inc. use nanotechnology to approach classical and novel drug delivery applications. We provide services for producing, formulating, and characterizing nanoparticles for a wide array of applications including, but not limited to, oral, pulmonary and parenteral delivery. Pharmaceutical Nanotechnology deals with emerging new technologies for developing customized solutions for drug delivery systems.
The worldwide theranostic nanomaterial market was evaluated to add up to about $16 billion in 2011 and $112 billion in 2012. The market ought to add up to about $188 bil0lion by 2017, and have a five-year compound yearly development rate (CAGR) of 10.8%.
- Track 6-1Characterization of Pharmaceutical Nanotools
- Track 6-2Engineering of Pharmaceutical Nanosystems
- Track 6-3Applications of Pharmaceutical Nanotools
- Track 6-4Challenges to Pharmaceutical Nanotechnology
- Track 6-5Future Prospects of Pharmaceutical Nanotechnology
A route of administration is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration. Routes can also be classified based on where the target of action is. Action may be topical (local), enteral (system-wide effect, but delivered through the gastrointestinal tract), or parenteral (systemic action, but delivered by routes other than the GI tract).
Routes of administration are usually classified by application location (or exposition). The route or course the active substance takes from application location to the location where it has its target effect is usually rather a matter of pharmacokinetics (concerning the processes of uptake, distribution, and elimination of drugs). Nevertheless, some routes, especially the transdermal or transmucosal routes are commonly referred to routes of administration. The location of the target effect of active substances is usually rather a matter of pharmacodynamics (concerning e.g. the physiological effects of drugs). Furthermore, there is also a classification of routes of administration that basically distinguishes whether the effect is local (in "topical" administration) or systemic (in "enteral" or "parenteral" administration).
- Track 7-1Advantages of advanced drug delivery
- Track 7-23D Printing Technologies
- Track 7-3Nucleic acid delivery technologies
- Track 7-4Drug delivery applications
- Track 7-5Advanced drug delivery
The area unit variety of motives for extending the merchandise development outside of the mature, developed economies (e.g. the EU and therefore the US) and most of them have faith in the high population and market potential of rising markets. Some reasons for this growing trend area unit result of the inevitable “patent cliff” that forces firms to any extend their reach and develop any. It's clear that rising markets supply nice market and population potential however at constant time cause sure challenges, as well as moral, GCP. Licensing in pharmaceutical production is mandatory step for pharmaceutical products. Regulatory matters is definitely acknowledged by the complete pharmaceutical community and authorities try to develop a cooperative model for harmonizing the Regulatory necessities across the regions so as to ease the world pharmaceutical development.
- Track 8-1Information on Compounding
- Track 8-2Drug Compliance Programs
- Track 8-3FDA guidance for clinical investigations
- Track 8-4Nicotine-Containing Products
- Track 8-5Regulatory Guidance Drug Registration and Listing
- Track 8-6PLR Requirements for Prescribing Information
Smart drug delivery is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. This means of delivery is largely founded on Nanomedicine, which plans to employ nanoparticle-mediated drug delivery in order to combat the downfalls of conventional drug delivery. These nanoparticles would be loaded with drugs and targeted to specific parts of the body where there is solely diseased tissue, thereby avoiding interaction with healthy tissue. The goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the diseased tissue. The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted release system releases the drug in a dosage form. The advantages to the targeted release system is the reduction in the frequency of the dosages taken by the patient, having a more uniform effect of the drug, reduction of drug side-effects, and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult and the reduced ability to adjust the dosages.
Targeted drug delivery systems have been developed to optimize regenerative techniques. The system is based on a method that delivers a certain amount of a therapeutic agent for a prolonged period of time to a targeted diseased area within the body. This helps maintain the required plasma and tissue drug levels in the body, thereby preventing any damage to the healthy tissue via the drug. The drug delivery system is highly integrated and requires various disciplines, such as chemists, biologists, and engineers, to join forces to optimize this system.
- Track 9-1Targeted Drug Delivery
- Track 9-2Gene Delivery
- Track 9-3Antibody Targeted-Drug Conjugates
- Track 9-4Blood Brain Barrier Delivery
- Track 9-5BioMEMS
- Track 9-62D and 3D Printing In Drug Delivery
- Track 9-7Self-Emulsifying Drug Delivery Systems (SEDDS
- Track 9-8Insulin Delivery
- Track 9-9Cancer Delivery
- Track 9-10Pulmonary Drug Delivery
- Track 9-11Skin Drug Delivery
- Track 9-12Mucosal Drug Delivery
- Track 9-13Proteins and Surfaces
- Track 9-14GMP/GCP Interface & GMP audits
Pharmaceutical quality affects every American. FDA regulates the quality of pharmaceuticals very carefully. The main regulatory standard for ensuring pharmaceutical quality is the Current Good Manufacturing Practice (CGMPs) regulation for human pharmaceuticals. Consumers expect that each batch of medicines they take will meet quality standards so that they will be safe and effective. Most people, however, are not aware of CGMPs, or how FDA assures that drug manufacturing processes meet these basic objectives. Recently, FDA has announced a number of regulatory actions taken against drug manufacturers based on the lack of CGMPs. This paper discusses some facts that may be helpful in understanding how CGMPs establish the foundation for drug product quality.
The worldwide market for biosimilars came to $1.7 billion in 2010 and $2.5 billion in 2011. The market is relied upon to reach $3.6 billion by 2016, a compound yearly development rate (CAGR) of 7.7%.
- Track 10-1Facts About Current Good Manufacturing Practices (cGMPs)
- Track 10-2Good Automated Manufacturing Practice (GAMP)
- Track 10-3FDA Good Manufacturing Practices
- Track 10-4GMP Requirements & Standards
A huge conflict has arisen between companies producing generic, more affordable drugs, and the big pharmaceutical companies. The multi-billion dollar companies from the pharmaceutical industry are claiming to be the holders of intellectual property rights for producing certain drugs. They are putting in their entire might to stop the production of generic drugs as it could cause a serious dent in their deep pockets.
The Big Pharma companies brand the drugs that they produce and sell them at exorbitant rates. Their claim that they need to be making profit to finance further research in the field of medicine is understandable. However, what needs to be curbed is the corporate avarice of these Big Pharma companies. The generic drug producing companies are using the exact same composition and formulas used to produce branded drugs for a fraction of the input cost, and thereby, are able to sell the drugs without any brand name at much affordable rates.
The worldwide generics division came to $269.8 billion in 2012. This segment is relied upon to reach $300.9 billion in 2013 and $518.5 billion in 2018, with a compound yearly development rate (CAGR) of 11.5%.
The worldwide pharma division came to $319.8 billion in 2012. This segment is relied upon to reach $400.9 billion in 2013 and $618.5 billion in 2018, with a compound yearly development rate (CAGR) of 15.5%.
- Track 11-1What is Big Pharma?
- Track 11-2Big Pharma Manufacturers
- Track 11-3Increasing Generics & Biosimilars
Drug absorption is set by the drug’s chemistry properties, formulation, and route of administration. Dosage forms (e.g. tablets, capsules, solutions), consisting of the drug and alternative ingredients, square measure developed to lean by numerous routes (e.g. oral, buccal, sublingual, rectal, parenteral, topical, inhalational). In spite of the route of administration, medicine should be in answer to be absorbed. Thus, solid forms (e.g. tablets) should be able to disintegrate and disaggregate. And Route of Administration in medicine and pharmacological medicine is that the path by that a drug, fluid, poison, or alternative substance is taken into the body. Routes of administration square measure typically classified by the placement at that the substance is applied. Common examples embody oral and endovenous administration. Effects of Disease on Drug disposition refer to all processes concerned within the absorption, distribution metabolism and excretion of medication in an exceedingly living organism.
The worldwide inpatient and outpatient clinical drug store mechanization advertise has developed to almost $3.8 billion in 2016 from $3.5 billion in 2015. The market is relied upon to develop at a five-year compound yearly development rate (CAGR) of 7.9% from 2016 to 2021, expanding to $5.5 billion in 2021.
- Track 12-1Clinical trials and drug information
- Track 12-2Outcome research and pharmacoeconomic studies
- Track 12-3Clinical case studies
- Track 12-4Role of pharmacist in communicating and counseling patients
Innovation—it is what everyone likes to talk about, but what does it really mean for millions of patients battling disease? Simply put, medical innovation can help patients live longer, healthier and more productive lives.
As one of the most research-intensive and science-driven industries in the U.S., the biopharmaceutical industry is committed to the research and development (R&D) of new treatments and cures for patients, including those who have serious unmet medical needs. With more than 7,000 innovative drugs in development worldwide by biopharmaceutical companies and over $500 billion invested in R&D since 2000, hope is certainly on the horizon.
Patients are not the only ones who benefit from new drug development. When new medicines keep patients healthier, the economy gets a boost from a healthier workforce, the cost of healthcare can go down and access improves. Perhaps above all else, medical advances give patients one essential ingredient for survival: hope.
The biopharmaceutical sector is the most research-intensive industry in the country, investing more than 10 times the amount of R&D per employee than manufacturing industries on average. With our rapidly increasing understanding of disease at the molecular level, science holds more promise for progress against many diseases today than at any time in history. The biopharmaceutical pipeline is demonstrating that promise.
The worldwide market for research and advancement is relied upon to develop from almost $86.5 billion in 2015 to $124.3 billion in 2020 at a yearly development rate of 7.5% from 2015-2020.
- Track 13-1New Medicines: Changing Lives and Managing Health Care Costs
- Track 13-2Research – Identifying a New Approach to Treat a Disease or Condition
- Track 13-3The Biopharmaceutical Research Ecosystem Drives Innovation
Pharmaceutical companies can play a central role in the digital revolution of healthcare. But capturing this opportunity requires identifying the right initiatives.
Pharmaceutical companies are running hard to keep pace with changes brought about by digital technology. Mobile communications, the cloud, advanced analytics, and the Internet of Things are among the innovations that are starting to transform the healthcare industry in the ways they have already transformed the media, retail, and banking industries. Pharma executives are well aware of the disruptive potential and are experimenting with a wide range of digital initiatives. Yet many find it hard to determine what initiatives to scale up and how, as they are still unclear what digital success will look like five years from now. This article aims to remedy that. We believe disruptive trends indicate where digital technology will drive the most value in the pharmaceutical industry, and they should guide companies as they build a strategy for digital success.
The digital pharma market is relied upon to reach $ 11.2 billion in 2013.This market is further anticipated that would develop upto $23.5 billion in 2018 with a compound yearly development rate (CAGR) of 16.1%.
- Track 14-1Pharma: Just Wetting its Feet into Digital waters
- Track 14-2Digital Pharma : A New Culture
- Track 14-3Digital Pharma & Customer Service
- Track 14-4Digital Pharma Opportunities & Challenges
- Track 14-5Digital’s Increasing Impact on Pharma Communications
Drug Manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs by pharmaceutical companies. The process of drug manufacturing can be broken down into a series of unit operations such as Milling, Granulation, Coating, Tablet pressing and others. Statistics are critical to the pharmaceutical industry, from clinical operations through manufacturing. However, clinical and manufacturing statistics represent entirely different worlds. Where they might be well staffed on the clinical side, some pharmaceutical companies today aren’t hiring qualified staff to analyze operations data, resulting in misapplied tools, inadequate CAPAs and superficial root cause analysis, all of which lead to financial loss and noncompliance.
The pharmaceutical manufacturing landscape has changed notably over the past decade and is continuing to evolve rapidly. Pharmaceutical manufacturers have begun to wield some new tools, nailing down new efficiencies and better drugs in the process.
The worldwide market for computerized material taking care of was esteemed at about $4.5 billion in 2013 and $4.8 billion in 2014. The aggregate market is anticipated to develop at a compound yearly development rate (CAGR) of 8.1% from 2014 through 2019 and reach $7.1 billion by 2019.
- Track 15-1Overview of Pharmaceutical Manufacturing Process
- Track 15-2Automation in Pharmaceutical Manufacturing
- Track 15-3Pharma Contract Manufacturing
It is carried out for the purpose of safety of the Drug products in order to keep them free from contamination, hinder microbial growth, and ensure product safety through the intended shelf life for the pharmaceuticals. Some common pharmaceutical packaging techniques include foil and heat sealing; polyester and olefin package printing; polyethylene and polypropylene printing; and flatbed die cutting.
The worldwide market for tissue building and recovery is relied upon to reach $60.8 billion by 2021 from $13.6 billion in 2016, ascending at a compound yearly development rate (CAGR) of 34.9% from 2016 through 2021.
- Track 16-1Package Design Research and New Trends In The Pharmaceutical Packaging
- Track 16-2Package Testing
- Track 16-3Packaging Material
- Track 16-4Packaging Machine
- Track 16-5Blister And Strip Packaging
- Track 16-6Defects In Packages
- Track 16-7Labeling of Packages
Quality is always an imperative prerequisite when we consider any product. Therefore, drugs must be manufactured to the highest quality levels. End-product testing by itself does not guarantee the quality of the product. Quality assurance techniques must be used to build the quality into the product at every step and not just tested for at the end. In pharmaceutical industry, Process Validation performs this task to build the quality into the product because according to ISO 9000:2000, it had proven to be an important tool for quality management of pharmaceuticals.
Quality cannot be adequately assured by in-process and finished inspections and testing but it should be built in to the manufacturing process. These processes should be controlled in order that the finished product meets all quality specifications. Validation is one of the important steps in achieving and maintaining the quality of the final product. If each step of production process is validated we can assure that the final product is of the best quality. Validation of the individual steps of the processes is called the process validation. Different dosage forms have different validation protocols.
- Track 17-1Strategies for Supply Chain Optimization
- Track 17-2Operational issues in the Pharmaceutical Supply Chain
- Track 17-3Strategic and Design Issues in the Pharmaceutical Supply Chain
- Track 17-4Supply Chain Design Summary
- Track 17-5Global Supply Chain Planning
Process Validation is one of the important steps in achieving and maintaining the quality of final product. It gives a higher degree of assurance.
The worldwide pharma process validation advertise has developed to $39.4 billion in 2014 from $29.3 billion in 2013. The market is required to develop at a five-year compound yearly development rate (CAGR) of 13.8% from 2015 to 2020, expanding from $50.6 billion in 2015 to $96.6 billion in 2020.
- Track 18-1Process Validation and Drug Quality
- Track 18-2Approach to Process Validation
- Track 18-3Statutory and Regulatory Requirements for Process Validation
- Track 18-4Types of Process Validation
- Track 18-5Validation Protocol and Report
Medico-Marketing involves promotion of pharmaceutical products. It facilitates to continuously update physicians, nurses and pharmacists regarding the safe and effective use of medicines. Medico marketing encompasses activities by medicos or organizations to actualize markets for pharmaceutical care.
The World Health Organization defines pharmaceutical promotion as “all information and persuasive activities executed by pharmaceutical manufacturers and distributors, attempting to affect the prescription, supply, purchase, and/or use of medical drugs”.
The worldwide liver infections therapeutics showcase totaled about $24.5 billion in 2014 and is anticipated to approach $33.8 billion by 2019, enlisting a compound yearly development rate (CAGR) of 6.7% through 2019.
- Track 19-1Pharma Market Structure
- Track 19-2Pharmaceutical Sales
- Track 19-3Rise in Pricing Pressures
- Track 19-4Increased Importance of Emerging Markets
- Track 19-5The Urge to Merge
The last few years have been a positive period overall for both the pharmaceutical and biotechnology industries. Most importantly, there has been a renaissance with regard to the increase in the number of new drugs approved and under development for the two segments of the business.
Many of these innovations are driven by new research methods and the growth of new therapeutic options, such as immune-related oncology drugs, personalized medicine, stem cells, and biologics. We are also witnessing the development of a greater number of drugs that cure diseases rather than just extend life.
The valuations of pharma and biotech companies in the public and M&A markets soared up until August/September of this year in part because of these positive developments. More recently, there has been a setback in public valuations due to the negative publicity about drug pricing.
The overall Pharmaceutical and Biotech Financial Outlook advertise totaled about $123 billion in 2014 and will keep on growing to reach almost $191 billion by 2019, showing a compound yearly development rate (CAGR) of 9.2% amid the conjecture time frame (2014 to 2019).
- Track 20-1Pharma’s Changing Landscape
- Track 20-2Boom in Biotech
- Track 20-3Pharma: What will the future bring?
- Track 20-4Biotech: What will the future bring?
A platform aimed to connect Entrepreneurs, Proposers and the Investors worldwide. It's intended to create and facilitate the most optimized and viable meeting place for engaging people in global business discussions, evaluation and execution of promising business ideas. An investor could be able to find out the highest potential investment opportunities globally, which provide good return on investment.